Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

RXR/RAR receptor modulators claimed by CIRD Galderma for skin and other disorders

Sep. 9, 1998

Biotech Australia announces encouraging early clinical trial results with leg ulcer treatment

Sep. 4, 1998

Leo describes potent vitamin D3 derivatives with low calcemic activity

Sep. 3, 1998

Keratinocyte growth factor to enter phase II clinical trials

Sep. 3, 1998

Access signs development agreement with ViroTex for amlexanox formulations

Sep. 1, 1998

Access signs licensing agreement with Paladin to market amlexanox in Canada

Aug. 27, 1998

Incert appears to prevent the formation of postoperative adhesions

Aug. 26, 1998

Toray reports kappa agonists for treating dermatological disorders

Aug. 25, 1998

Access licensee files for U.K. approval of amlexanox oral paste

Aug. 24, 1998

Wound-healing asiatic acid derivatives under investigation at Dong Kook

Aug. 24, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...